ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL

Leukemia

Volumn 15, Issue 4, 2001, Pages 575-582

  Shteper, P J ^a   Siegfried, Z ^a   Asimakopoulos, F A ^a   Palumbo, G A ^b   Rachmilewitz, E A ^a   Ben Neriah, Y ^c   Ben Yehuda, D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF CATANIA   (Italy)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

ABL; Acute lymphoblastic leukemia; Chronic myeloid leukemia; Methylation; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; BISULFITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLAST CELL CRISIS; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA MODIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; METHYLATION; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SAMPLE; STATISTICAL MODEL;

EID: 0035072763     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402026     Document Type: Article

References (44)

1. Heritable fragile sites in cancer
2. BCR/ABL rearrangement and leukemia phenotype
3. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia
4. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
5. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia
6. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration
7. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
8. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
9. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL
10. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia
11. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia
12. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia
13. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
14. Significance of the P210 vs P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
15. Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance
16. Disease progression in chronic myelogenous leukemia (CML) is linked to methylation of the ABL promoter
17. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
18. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells
19. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
20. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p21Obcr/abl: A novel transgenic model for human Ph1-positive leukemias
21. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
22. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia
23. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation
24. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation
25. Chromosomal breakpoints within the first intron of the ABL gene are nonrandom in patients with chronic myelogenous leukemia
26. Ph1-positive, bcr-negative acute leukemias: Clustering of breakpoints on chromosome 22 in the 3′ end of the BCR gene first intron
27. P15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing
28. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene
29. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications
30. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer
31. MSH2 deficient mice are viable and susceptible to lymphoid tumours
32. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility
33. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements
34. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability
35. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
36. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
37. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
38. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia
39. DNA methylation patterns in the calcitonin gene region at first diagnosis and at relapse of acute lymphoblastic leukemia (ALL)
40. P16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation
41. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia
42. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation
43. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia
44. Ataxia-telangiectasia and T-cell leukemias: No evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL